Precigen to Participate in the 2024 Cantor Global Healthcare Conference
Precigen (Nasdaq: PGEN), a biopharmaceutical company focused on innovative gene and cell therapies, announced its participation in the 2024 Cantor Global Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, will engage in a fireside chat on September 18, 2024, from 9:45 to 10:15 AM ET in New York.
The conference, scheduled for September 17-19, 2024, provides a platform for Precigen to showcase its advancements in precision medicine. Precigen specializes in developing therapies for immuno-oncology, autoimmune disorders, and infectious diseases using cutting-edge gene and cell therapy technologies. Interested parties can access event details through Precigen's website in the Events & Presentations section.
Precigen (Nasdaq: PGEN), un'azienda biofarmaceutica focalizzata su terapie innovative con geni e cellule, ha annunciato la sua partecipazione alla Conferenza Globale sulla Sanità Cantor 2024. Helen Sabzevari, PhD, Presidente e CEO di Precigen, parteciperà a un colloquio informale il 18 settembre 2024, dalle 9:45 alle 10:15 AM ET a New York.
La conferenza, in programma dal 17 al 19 settembre 2024, offre una piattaforma per permettere a Precigen di mostrare i suoi progressi nella medicina di precisione. Precigen si specializza nello sviluppo di terapie per l'immuno-oncologia, i disturbi autoimmuni e le malattie infettive utilizzando tecnologie all'avanguardia per la terapia genica e cellulare. Le parti interessate possono accedere ai dettagli dell'evento attraverso il sito web di Precigen nella sezione Eventi & Presentazioni.
Precigen (Nasdaq: PGEN), una empresa biofarmacéutica centrada en terapias innovadoras de genes y células, anunció su participación en la Conferencia Global de Atención Médica Cantor 2024. Helen Sabzevari, PhD, Presidenta y CEO de Precigen, participará en una charla informal el 18 de septiembre de 2024, de 9:45 a 10:15 AM ET en Nueva York.
La conferencia, programada del 17 al 19 de septiembre de 2024, proporciona una plataforma para que Precigen presente sus avances en medicina de precisión. Precigen se especializa en el desarrollo de terapias para inmuno-oncología, trastornos autoinmunes y enfermedades infecciosas utilizando tecnologías de terapia génica y celular de vanguardia. Las partes interesadas pueden acceder a los detalles del evento a través del sitio web de Precigen en la sección de Eventos y Presentaciones.
프레시겐 (Nasdaq: PGEN), 혁신적인 유전자 및 세포 치료에 중점을 둔 생물 의약품 회사가 2024 캔토 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 헬렌 삽제바리, PhD, 프레시겐의 회장 겸 CEO는 2024년 9월 18일 오전 9시 45분부터 10시 15분(ET)까지 뉴욕에서 대화에 참여할 것입니다.
2024년 9월 17일부터 19일까지 예정된 이번 컨퍼런스는 프레시겐이 정밀 의학에서의 발전을 선보일 수 있는 플랫폼을 제공합니다. 프레시겐은 면역 종양학, 자가 면역 질환 및 감염병 치료를 위한 최첨단 유전자 및 세포 치료 기술을 사용하여 치료법을 개발하는 데 전문화되어 있습니다. 관심 있는 당사자는 프레시겐 웹사이트 이벤트 및 발표 섹션을 통해 이벤트 세부정보에 액세스할 수 있습니다.
Precigen (Nasdaq: PGEN), une entreprise biopharmaceutique axée sur les thérapies innovantes par gènes et cellules, a annoncé sa participation à la Conférence Mondiale sur la Santé Cantor 2024. Helen Sabzevari, PhD, Présidente et CEO de Precigen, participera à un entretien le 18 septembre 2024, de 9h45 à 10h15 ET à New York.
La conférence, prévue du 17 au 19 septembre 2024, offre une plateforme à Precigen pour présenter ses avancées en médecine de précision. Precigen est spécialisée dans le développement de thérapies pour l'immuno-oncologie, les troubles auto-immuns et les maladies infectieuses en utilisant des technologies de thérapie génique et cellulaire de pointe. Les parties intéressées peuvent accéder aux détails de l'événement via le site web de Precigen dans la section Événements & Présentations.
Precigen (Nasdaq: PGEN), ein biopharmazeutisches Unternehmen, das sich auf innovative Gene- und Zelltherapien konzentriert, gab seine Teilnahme an der 2024 Cantor Global Healthcare Conference bekannt. Helen Sabzevari, PhD, Präsidentin und CEO von Precigen, wird am 18. September 2024 von 9:45 bis 10:15 Uhr ET in New York an einem informellen Gespräch teilnehmen.
Die Konferenz, die vom 17. bis 19. September 2024 stattfindet, bietet eine Plattform für Precigen, um seine Fortschritte in der Präzisionsmedizin zu präsentieren. Precigen ist auf die Entwicklung von Therapien für immunonkologische, autoimmune Erkrankungen und Infektionskrankheiten unter Verwendung modernster Technologien der Gen- und Zelltherapie spezialisiert. Interessierte Parteien können über die Webseite von Precigen im Bereich Veranstaltungen & Präsentationen auf die Einzelheiten der Veranstaltung zugreifen.
- None.
- None.
Participants may view details for the event through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on X @Precigen, LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-2024-cantor-global-healthcare-conference-302249385.html
SOURCE Precigen, Inc.
FAQ
When is Precigen (PGEN) participating in the 2024 Cantor Global Healthcare Conference?
What is the focus of Precigen's (PGEN) research and development?
How can investors access information about Precigen's (PGEN) participation in the 2024 Cantor Global Healthcare Conference?
What is the date range for the 2024 Cantor Global Healthcare Conference where Precigen (PGEN) is participating?
